Remove 2022 Remove Immunity Remove Labelling
article thumbnail

Monkeypox update – August 2022

European Pharmaceutical Review

On 23 July 2022, the World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus, declared the multi-country outbreak of monkeypox a public health emergency of international concern. As of 2 August 2022, the UK had 2,739 confirmed cases, 4 the majority occurring within London, England. Current case rates.

article thumbnail

FDA Approvals: September 2022 Recap

Digital Pharmacist

Date of Approval: 9/30/2022. Date of Approval: 9/29/2022. Date of Approval: 9/22/2022. Date of Approval: 9/21/2022. Date of Approval: 9/14/2022. Date of Approval: 9/9/2022. Below we will be listing some of the new drug therapy advances and approvals that the FDA had in the month of September.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck acquires Prometheus Biosciences

Express Pharma

Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialisation of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

The management of SLE and LN consists largely of treatment options that are based on highly efficacious steroids or immune-suppressive therapy with an undesirable safety profile, which includes accrued organ damage, infections and cancer. in 2018 across the 7MM despite being an off-label therapy for lupus.

Labelling 111
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccines 134
article thumbnail

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

pharmaphorum

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an accelerated review by the EMA. . The post Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon appeared first on.

article thumbnail

New Legislation Would Cut Off Access To The Courts And Immunize FDA Actions From Timely Judicial Review

FDA Law Blog: Biosimilars

Senate Committee on Health, Education, Labor and Pensions (“Senate HELP”) is scheduled to take up legislation that could significantly limit access to the courts and immunize critical FDA decisions from timely judicial review. 1067, which first reared its head in Spring 2022 as an amendment to S.4348, Shumsky — On May 2nd, the U.S.